NCT00426855View on ClinicalTrials.gov

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

June 30, 2009

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

Bendamustine

starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w

DRUG

Bortezomib

weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w

All Listed Sponsors
collaborator

Kantonsspital Aarau

OTHER

lead

Peter Moosmann

OTHER

NCT00426855 - Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) | Biotech Hunter | Biotech Hunter